PMID- 24434058
OWN - NLM
STAT- MEDLINE
DCOM- 20140428
LR  - 20240213
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 132
IP  - 3
DP  - 2014 Mar
TI  - Oncolytic vaccinia virotherapy for endometrial cancer.
PG  - 722-9
LID - S0090-8258(14)00020-1 [pii]
LID - 10.1016/j.ygyno.2014.01.009 [doi]
AB  - OBJECTIVE: Oncolytic virotherapy is a promising modality in endometrial cancer 
      (EC) therapy. In this study, we compared the efficacy of the Copenhagen and Wyeth 
      strains of oncolytic vaccinia virus (VV) incorporating the human thyroidal sodium 
      iodide symporter (hNIS) as a reporter gene (VVNIS-C and VVNIS-W) in EC. METHODS: 
      Infectivity of VVNIS-C and VVNIS-W in type I (HEC1A, Ishikawa, KLE, RL95-2, and 
      AN3 CA) and type II (ARK-1, ARK-2, and SPEC-2) human EC cell lines was evaluated. 
      Athymic mice with ARK-2 or AN3 CA xenografts were treated with one intravenous 
      dose of VVNIS-C or VVNIS-W. Tumor regression and in vivo infectivity were 
      monitored via NIS expression using SPECT-CT imaging. RESULTS: All EC cell lines 
      except KLE were susceptible to infection and killing by VVNIS-C and VVNIS-W in 
      vitro. VVNIS-C had higher infectivity and oncolytic activity than VVNIS-W in all 
      cell lines, most notably in AN3 CA. Intravenous VVNIS-C was more effective at 
      controlling AN3 CA xenograft growth than VVNIS-W, while both VVNIS-C and VVNIS-W 
      ceased tumor growth and induced tumor regression in 100% of mice bearing ARK-2 
      xenografts. CONCLUSION: Overall, VVNIS-C has more potent oncolytic viral activity 
      than VVSIN-W in EC. VV appears to be most active in type II EC. Novel therapies 
      are needed for the highly lethal type II EC histologies and further development 
      of a VV clinical trial in type II EC is warranted.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Liu, Yu-Ping
AU  - Liu YP
AD  - Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Wang, Jiahu
AU  - Wang J
AD  - Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 
      Ottawa, ON KlY 4E9, Canada.
FAU - Avanzato, Victoria A
AU  - Avanzato VA
AD  - Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA; Pennsylvania 
      State University, State College, PA, USA.
FAU - Bakkum-Gamez, Jamie N
AU  - Bakkum-Gamez JN
AD  - Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
FAU - Russell, Stephen J
AU  - Russell SJ
AD  - Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA; Division of 
      Hematology, Mayo Clinic, Rochester, MN, USA.
FAU - Bell, John C
AU  - Bell JC
AD  - Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 
      Ottawa, ON KlY 4E9, Canada.
FAU - Peng, Kah-Whye
AU  - Peng KW
AD  - Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA; Department of 
      Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA. Electronic address: 
      peng.kah@mayo.edu.
LA  - eng
GR  - R01 CA136547/CA/NCI NIH HHS/United States
GR  - R01CA136547/CA/NCI NIH HHS/United States
GR  - K12 HD065987/HD/NICHD NIH HHS/United States
GR  - P30CA015083/CA/NCI NIH HHS/United States
GR  - R01 CA129193/CA/NCI NIH HHS/United States
GR  - P30 CA015083/CA/NCI NIH HHS/United States
GR  - P50CA136393/CA/NCI NIH HHS/United States
GR  - R01CA129193/CA/NCI NIH HHS/United States
GR  - P50 CA136393/CA/NCI NIH HHS/United States
GR  - K12HD065987/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20140114
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Symporters)
RN  - 4XE5NDT4K1 (sodium-iodide symporter)
SB  - IM
MH  - Animals
MH  - Endometrial Neoplasms/*therapy/*virology
MH  - Female
MH  - Genes, Reporter
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Oncolytic Virotherapy/*methods
MH  - Symporters/genetics
MH  - Vaccinia virus/genetics/pathogenicity/*physiology
MH  - Xenograft Model Antitumor Assays
PMC - PMC3977925
MID - NIHMS561301
OTO - NOTNLM
OT  - Copenhagen strain
OT  - Endometrial cancer
OT  - Vaccinia virus
OT  - Virotherapy
OT  - Wyeth strain
COIS- Conflict of Interest Drs Russell, Wang, Bell and Peng, and Mayo Clinic have a 
      financial interest in this research.
EDAT- 2014/01/18 06:00
MHDA- 2014/04/29 06:00
PMCR- 2015/03/01
CRDT- 2014/01/18 06:00
PHST- 2013/12/11 00:00 [received]
PHST- 2014/01/08 00:00 [revised]
PHST- 2014/01/09 00:00 [accepted]
PHST- 2014/01/18 06:00 [entrez]
PHST- 2014/01/18 06:00 [pubmed]
PHST- 2014/04/29 06:00 [medline]
PHST- 2015/03/01 00:00 [pmc-release]
AID - S0090-8258(14)00020-1 [pii]
AID - 10.1016/j.ygyno.2014.01.009 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2014 Mar;132(3):722-9. doi: 10.1016/j.ygyno.2014.01.009. Epub 2014 
      Jan 14.